Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.

Cytokine therapy is promising for treating skin conditions like vitiligo and psoriasis.

The skin's immune system helps it regenerate and fight infections.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

Using a combination of AMD3100 and FK506 can speed up and improve wound healing in diabetic rats.

Th22 cells are essential for Tβ15-induced hair growth in mice.

Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

IP-PA1 helps grow hair in mice and affects human cell growth-related genes differently than traditional hair growth treatments.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

JAK inhibitors might help treat alopecia areata.

ACTH promotes hair growth in mink, but α-MSH does not.

Topical tacrolimus reduces certain growth factors in hair follicles.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Certain substances can help skin cells become anti-inflammatory, aiding in tissue repair.

UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

Improving nerve and immune interactions may help heal chronic wounds.

Keeping human skin stem cells is easier with low temperatures and mTOR inhibition.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Hydrogel scaffolds can help wounds heal better and grow hair.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.